April 2023 - Page 4 of 6 - NetworkNewsWire

FridayApr 14, 2023 10:30 am

DGE’s 3rd KOL Engagement Forum: Learn and Network with Leaders in the Medical Affairs and MSL Community

In a time of unprecedented public fear and distrust of institutions, life science companies must be more careful than ever to cultivate KOL (Key Opinion Leader) relationships that lend credibility to their products. As regulations grow stricter, and demand for niche products and personalized treatment rises, KOLs are set to play an even more important role in winning acceptance among the medical community. The increasing trend toward personalized healthcare research online and via other forms of media has created a greater need for medical product developers to competitively market their messages across a wide spectrum of media audiences and prioritize…

FridayApr 14, 2023 9:45 am

Lidar Pioneer Cepton, Inc. (NASDAQ: CPTN) Bridges Technological Gaps to Advance Mass Market ADAS Adoption

Cepton unveiled its Vista(R)-X120 Plus earlier this year at CES 2023, one of the largest tech tradeshows this year, where it was named a CES 2023 innovation award honoree for next-generation lidar products Vista(R)-X120 Plus features a wider field of view, software-definable regions of interest, and faster data transmission with a target price below $500, enabling high-volume production and faster mass-market adoption Vista(R)-X120 Plus is smaller and lighter, allowing for seamless integration without significantly affecting vehicle design Cepton collaborates with many global OEMS, and recently won the largest commercial lidar deployment contract in the tolling sector to date Advanced Driver…

FridayApr 14, 2023 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Discusses Positive Results from In Vivo Proof-of-Concept Study of Its Anti-COVID-19 NanoAb Therapy and Additional Pipeline Plans at BIO-Europe Spring

BiondVax Pharmaceuticals is a biotechnology company developing, manufacturing, and commercializing innovative NanoAb immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases Company CEO Amir Reichman recently presented at the BIO-Europe Spring conference, where he talked about BiondVax’s successful preclinical in vivo results of its innovative inhaled COVID-19 treatment and additional pipeline plans The in vivo results have shown that the company’s inhaled COVID-19 therapy, formulated using alpaca-derived nanosized antibodies (“NanoAbs”), resulted in milder and shorter illness, virtually eliminated the virus from the lungs, and prophylactically protected against illness Since he was appointed CEO in early 2021, Reichman…

ThursdayApr 13, 2023 10:30 am

DGE’s 7th Digital Strategy & Innovation for Medical Affairs Summit to Focus on the Cultural Digital Revolution For Medical Affairs Teams

DGE invites industry executives, policymakers, and health providers, to attend the 7th Digital Strategy & Innovation for Medical Affairs Summit to be held in Philadelphia from May 17-18, 2023, in addition to being live streamed. The 7th Digital Strategy & Innovation for Medical Affairs Summit is the leading and most influential industry conference for transforming the MA department into a division that executes advanced policies and patient centricity. In a world where business models and medical science are increasingly complicated and data-driven, MA teams have emerged as the key players not only in ensuring the success of their companies but…

ThursdayApr 13, 2023 9:45 am

Coyuchi Inc. Recently-Opened Palo Alto Store Helps Bring To Life The Coyuchi Luxury Experience

Marcus Chung, the brand’s first COO, who is leading the company’s growth strategy, played an integral role in the opening of the Palo Alto store Coyuchi is pushing the organic textile market forward through its circular business model, the creation of The Coyuchi Climate Council, and the foundation of C4: The California Cotton & Climate Coalition Regulation A+ funding is being used to expand Coyuchi’s enterprise value through expanded marketing, product category expansion, and its physical store presence that brings a direct-to-consumer experience to life, along with B2B strategic partnerships with wholesalers and online marketplaces Coyuchi, the gold standard in…

ThursdayApr 13, 2023 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Global Trial Targets Unmet Medical Need in Arresting GBM Brain Cancer

Glioblastoma (“GBM”), an aggressive and generally fatal brain cancer, has attracted attention as a significant unmet medical need because of its incurability, claiming the lives of more than 200,000 patients worldwide each year CNS Pharmaceuticals is in the middle of a potentially pivotal global Phase 2 clinical trial for its drug candidate, a novel anthracycline called Berubicin that is apparently unique in its ability to cross the blood-brain barrier to target central nervous system tumors CNS’s clinical trial sites have begun enrolling patients in the United States, France, Spain and Switzerland, with sites prepared to receive patients in Italy as…

WednesdayApr 12, 2023 9:45 am

Lift Toronto 2023 Cannabis Conference and Expo Announces Speakers and Sessions; Registration Now Open

Thousands of cannabis industry and community members will gather at the Metro Toronto Convention Centre, June 1-3, for three high-energy days of discovery, education, entertainment and more. The highly anticipated Lift Toronto 2023 Cannabis Conference and Expo, which will bring together thousands of cannabis industry professionals and consumers from all parts of the cannabis ecosystem, returns to the Metro Toronto Convention Centre from June 1-3, 2023. Hundreds of exhibiting companies will showcase the latest in cannabis products, services and innovations; industry leaders and fresh voices will take the stage; and new experiences and activations will lead to Lift’s signature a-ha…

WednesdayApr 12, 2023 9:00 am

SideChannel Inc. (SDCH) Offers Unique Suite of Cybersecurity and Privacy Services On An As-Needed Basis for Optimum Affordability

SideChannel is a cybersecurity services company driven by a stated mission to make cybersecurity simple, accessible, effective, and affordable The company targets small and mid-sized businesses that are often priced out of quality cybersecurity services SideChannel’s services include vCISO services, vCPO services, risk assessment, cybersecurity compliance, and third-party risk management By providing these services, the company empowers clients to reduce risks, balance their security and privacy services investment, and build the confidence needed to operate with business-aligned security and privacy SideChannel (OTCQB: SDCH), a company focused on addressing cybersecurity challenges for mid-market companies, startups, and small enterprises normally priced out…

TuesdayApr 11, 2023 10:30 am

GeoSolar Technologies Inc. Advances Home Renewable Systems That Reduce Carbon Use and Potentially Eliminate Utility Bills

GeoSolar’s SmartGreen(TM) whole-home renewable energy system potentially reduces dependence on fossil fuels while lowering or even completely eliminating utility bills The SmartGreen(TM) system includes photovoltaic solar panels, geothermal ground loops, integrated air ducts and floor loops, CERV(R) air filtration, upgrades to lighting systems, windows, insulation The SmartGreen(TM) system can be integrated into new construction projects or existing buildings GeoSolar plans to market SmartGreen(TM) to over 120 million homes across the U.S. with various financing options, tax deductions, utility incentives The Intergovernmental Panel on Climate Change (“IPCC”) has stated that there is over a 95% probability that the observed warming of…

TuesdayApr 11, 2023 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Its Potentially Pivotal Global GBM Trial, Reports No Exposure to SVB Issues

CNS Pharmaceuticals recently announced it had enrolled the first patient in Switzerland as part of its ongoing potentially pivotal global GBM trial The adaptive, multicenter, open-label, randomized controlled trial is evaluating Berubicin for the treatment of recurrent GBM, the most common primary brain cancer, compared to Lomustine, the current standard of care The enrollment moves the company closer to its goal of undertaking an interim analysis expected in the third quarter of 2023 So far, CNS Pharmaceuticals has opened over 40 of 59 planned clinical trial sites selected across Switzerland, Spain, France, Italy, and the U.S. As an aside, the…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

Month: April 2023